AstraZeneca PLC received an early holiday present in Germany, with its clot buster Brilique (ticagrelor) becoming the first drug to successfully clear the hurdle of the Joint Federal Committee’s (G-BA’s) added benefit assessment.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?